Access to Medicine Foundation

Access to Medicine Foundation
Name	Access to Medicine Foundation
Formation	2003
Type	Non-profit organization
Headquarters	Amsterdam, Netherlands
Region served	Global
Leader title	Director

Access to Medicine Foundation is an independent non-profit organization based in Amsterdam focusing on pharmaceutical access and public health. It produces the Access to Medicine Index and engages with pharmaceutical companies, civil society, international organizations, and investors to improve availability, affordability, and appropriate use of medicines in low- and middle-income countries. The organization works at the intersection of global health, corporate accountability, and development policy.

History

The Foundation was established in 2003 following discussions involving Royal Tropical Institute, Dutch Ministry of Foreign Affairs, Bill & Melinda Gates Foundation, World Health Organization, and GAVI, the Vaccine Alliance stakeholders. Early collaborators included Médecins Sans Frontières, Oxfam, Clinton Foundation, and UNITAID, reflecting a convergence of interests among philanthropy, multilateralism, and public-private partnerships seen in the early 21st century. Initial projects were informed by precedents such as the Doha Declaration on the TRIPS Agreement and Public Health and advocacy by actors like Paul Farmer and Amartya Sen on health equity. Over time the Foundation expanded its remit to cover non-communicable diseases and antimicrobial resistance, responding to trends also highlighted by United Nations General Assembly high-level meetings on antimicrobial resistance and the Sustainable Development Goals.

Mission and Objectives

The Foundation's mission emphasizes accountability of the pharmaceutical industry, engagement with investors, and collaboration with civil society organizations such as Global Health Council, Treatment Action Campaign, and Results International. Objectives include assessing company policies, incentivizing corporate transparency, and promoting research and development for neglected diseases championed by groups like Drugs for Neglected Diseases initiative and Wellcome Trust. The Foundation frames its work within policy instruments and initiatives tied to World Health Organization guidance, UNICEF procurement practices, and norms promoted by World Bank and European Commission health programmes.

Access to Medicine Index

The flagship product is the Access to Medicine Index, a comparative benchmarking tool that evaluates pharmaceutical companies including GlaxoSmithKline, Novartis, Pfizer, Johnson & Johnson, Roche, Sanofi, AstraZeneca, Merck & Co., and Bayer. The Index methodology draws on data standards and frameworks established by Global Reporting Initiative, International Federation of Pharmaceutical Manufacturers & Associations, and recommendations from Lancet commissions. Index cycles have prompted dialogues with corporations, investors such as BlackRock and Vanguard, and shareholders using mechanisms similar to those advocated by ShareAction and Institutional Shareholder Services. The Index has been cited in analyses by The Economist, Financial Times, Nature, and policy debates in forums including World Health Assembly.

Programs and Initiatives

Programs span company benchmarking, collaborative convenings, and targeted initiatives on priorities such as antimicrobial resistance, access to HIV treatments, tuberculosis portfolios, and vaccine equity. The Foundation partners with entities like UNITAID, GHIT Fund, Coalition for Epidemic Preparedness Innovations, and Partners In Health on projects to accelerate R&D for neglected indications. Initiatives include engagement with national procurement agencies such as South African National Department of Health, supply chain actors like UNICEF Supply Division, and regulatory harmonization efforts with African Medicines Agency and European Medicines Agency. Capacity-building efforts reference standards from Good Manufacturing Practice regulators including U.S. Food and Drug Administration and Medicines and Healthcare products Regulatory Agency.

Governance and Funding

Governance is overseen by a board composed of representatives from foundations, academia, and civil society, including ties to institutions such as London School of Hygiene & Tropical Medicine, Harvard University, and University of Cape Town. Funding sources include philanthropic donors like the Bill & Melinda Gates Foundation and Wellcome Trust, multilateral partners such as UNITAID and European Commission, and private foundations including Bloomberg Philanthropies and Robert Wood Johnson Foundation. The Foundation maintains independence through transparency policies aligned with practices from Charities Aid Foundation and reporting norms used by Charity Navigator-audited organizations.

Impact and Criticism

Impact claims include influencing corporate policies on differential pricing, patent licensing practices reminiscent of Medicines Patent Pool, and expanded company commitments on neglected disease portfolios, noted in studies by Chatham House and Center for Global Development. The Index has been used by investors and procurement agencies to inform decisions, and its methodology has catalyzed public debates in venues such as World Economic Forum and United Nations fora. Criticism has come from academic commentators and activist groups including Médecins Sans Frontières and Knowledge Ecology International alleging limitations in transparency, potential methodological bias, and the challenges of attributing outcomes to benchmarking alone—echoing critiques leveled at corporate accountability tools discussed in Harvard Business Review and Stanford Social Innovation Review. Ongoing reforms aim to address these criticisms by refining metrics and increasing stakeholder participation, with input from regulators like World Health Organization and funders such as GAVI, the Vaccine Alliance.

Category:Non-profit organizations based in the Netherlands Category:Global health organizations